CVD 1208S-122 is a diarrhea vaccine candidate comprised of a weakened live strain of Shigella expressing protective antigens from ETEC
To prevent the contraction of serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC)
The research will test the safety, tolerability and potential protection of oral doses of the prototype Shigella-ETEC vaccine. The trials will include testing how the immune system in healthy adults responds to varying doses of the vaccine. The goal is to determine the safety and best dosing of the vaccine, which could ultimately protect millions of people around the world who are at most risk to diarrheal diseases.